BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 7558957)

  • 1. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
    O'Neill BP; O'Fallon JR; Earle JD; Colgan JP; Brown LD; Krigel RL
    Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):663-73. PubMed ID: 7558957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
    Mead GM; Bleehen NM; Gregor A; Bullimore J; Shirley D; Rampling RP; Trevor J; Glaser MG; Lantos P; Ironside JW; Moss TH; Brada M; Whaley JB; Stenning SP
    Cancer; 2000 Sep; 89(6):1359-70. PubMed ID: 11002232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
    Laack NN; Ballman KV; Brown PB; O'Neill BP;
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1429-39. PubMed ID: 16863926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.
    Bessell EM; Graus F; Punt JA; Firth JL; Hope DT; Moloney AJ; Lopez-Guillermo A; Villa S
    J Clin Oncol; 1996 Mar; 14(3):945-54. PubMed ID: 8622044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
    N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma.
    Shikama N; Oguchi M; Isobe K; Nakamura K; Tamaki Y; Hasegawa M; Kodaira T; Sasaki S; Kagami Y;
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):217-22. PubMed ID: 16814951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
    Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
    J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients.
    Singhal D; Witham TF; Germanwala A; Flickinger JC; Schiff D; Kondziolka D
    Can J Neurol Sci; 2002 May; 29(2):147-53. PubMed ID: 12035835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
    Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
    Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system lymphomas: progress in chemotherapy and radiotherapy.
    Brada M
    Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):769-71. PubMed ID: 7558971
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.